Market
Will Novo Nordisk boost Wegovy and Ozempic production by 20% by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk's official production reports or credible industry analysis
Story
Novo Nordisk to Finalize $16.5 Billion Catalent Acquisition of Three Manufacturing Sites After FTC Approval
Dec 14, 2024, 03:45 PM
Novo Nordisk is poised to finalize its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's (FTC) decision not to challenge the $16.5 billion acquisition by Novo Holdings of Catalent. This acquisition is expected to bolster Novo Nordisk's production capabilities, particularly in response to the growing demand for its anti-obesity drugs, including Wegovy and Ozempic. The deal has cleared all regulatory closing conditions, allowing Novo Nordisk to proceed with its plans to enhance its manufacturing capacity. The acquisition is strategically significant as Catalent is a key subcontractor in the production of Wegovy, which has seen increased demand due to its popularity in treating obesity.
View original story
Similar markets
Safety label update • 25%
Other regulatory actions • 25%
Product recall • 25%
No action taken • 25%
No • 50%
Yes • 50%
No significant change • 25%
Significant increase • 25%
Moderate increase • 25%
Decrease • 25%
Haemophilia and multiple other product types • 25%
Only haemophilia products • 25%
Haemophilia and one other product type • 25%
No production • 25%
